Kennedy Capital Management LLC Takes $2.55 Million Position in Inhibrx, Inc. (NASDAQ:INBX)

Kennedy Capital Management LLC acquired a new position in shares of Inhibrx, Inc. (NASDAQ:INBX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 165,681 shares of the company’s stock, valued at approximately $2,551,000. Kennedy Capital Management LLC owned about 1.14% of Inhibrx at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of INBX. Arbiter Partners Capital Management LLC acquired a new position in Inhibrx in the fourth quarter valued at approximately $433,000. Yakira Capital Management Inc. purchased a new position in shares of Inhibrx during the 4th quarter worth $557,000. Russell Investments Group Ltd. acquired a new stake in shares of Inhibrx during the 4th quarter worth about $837,000. Wells Fargo & Company MN purchased a new stake in Inhibrx in the 4th quarter valued at about $102,000. Finally, Rangeley Capital LLC purchased a new position in Inhibrx during the fourth quarter worth about $761,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Inhibrx Price Performance

INBX opened at $11.61 on Monday. The stock’s 50-day moving average price is $13.25 and its 200 day moving average price is $14.31. Inhibrx, Inc. has a 12-month low of $10.80 and a 12-month high of $35.02.

Inhibrx (NASDAQ:INBX) last announced its quarterly earnings data on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21). The company had revenue of $0.10 million for the quarter. Analysts expect that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.